– USA, CA – Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Geoffrey Parker has been appointed to the Sunesis Board of Directors. Mr. Parker brings over 30 years of finance and executive leadership experience to the Board including, most recently, serving as Executive Vice President and Chief Financial Officer of Anacor Pharmaceuticals, Inc., which he joined in 2010 at the time of its initial public offering. Sunesis also announced that Helen Kim stepped down from her position as a Director.
“Geoff’s extensive experience in healthcare finance and operations will be invaluable to Sunesis,” said Daniel Swisher, Chief Executive Officer of Sunesis. “We welcome Geoff to our Board and look forward to his strategic counsel as we work towards achieving our future corporate objectives including in 2016 moving vosaroxin through the regulatory approval process in Europe, entering into an ex-US partnership and advancing our kinase inhibitor pipeline to meaningful data milestones. At the same time, we would like to thank Helen Kim for her significant contributions as a Director.”
“I am delighted to be joining Sunesis as a Board Member,” stated Mr. Parker. “Sunesis is at a pivotal point in its evolution with a broad pipeline of differentiated cancer therapeutics and an experienced management team and Board of Directors. I look forward to contributing to the achievement of its strategic plan and supporting Sunesis’ future growth.”
During his five years at Anacor from 2010 to 2015, Mr. Parker helped lead the company during the FDA approval and commercial launch of KERYDIN® (tavaborole) and was instrumental in securing partnerships and financing the company’s product pipeline. Prior to Anacor, Mr. Parker had significant transactional and advisory experience working with life sciences companies in various capacities at Goldman Sachs, leading the firm’s West Coast Healthcare Investment Banking practice for twelve years.
Mr. Parker currently serves as a member of the Board of Directors of ChemoCentryx, Inc. He received an A.B. from Dartmouth College in Engineering Sciences and Economics and an M.B.A. from the Stanford Graduate School of Business.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of people with cancer and is currently pursuing regulatory approval in Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 and older. In addition, the company is advancing its kinase-inhibitor pipeline of novel targeted therapies into the clinic.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.